Eversept Partners LLC acquired a new position in shares of Radius Health Inc (NASDAQ:RDUS) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 194,501 shares of the biopharmaceutical company’s stock, valued at approximately $6,179,000. Radius Health accounts for about 5.1% of Eversept Partners LLC’s investment portfolio, making the stock its 6th largest position.
A number of other institutional investors have also modified their holdings of the business. State Street Corp grew its position in Radius Health by 12.9% during the 2nd quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after purchasing an additional 213,399 shares during the last quarter. TimesSquare Capital Management LLC grew its position in Radius Health by 184.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,610,365 shares of the biopharmaceutical company’s stock worth $62,080,000 after purchasing an additional 1,044,615 shares during the last quarter. Orbimed Advisors LLC boosted its holdings in shares of Radius Health by 59.5% in the third quarter. Orbimed Advisors LLC now owns 1,122,800 shares of the biopharmaceutical company’s stock valued at $43,284,000 after acquiring an additional 418,700 shares in the last quarter. Pictet Asset Management Ltd. boosted its holdings in shares of Radius Health by 24.7% in the third quarter. Pictet Asset Management Ltd. now owns 799,672 shares of the biopharmaceutical company’s stock valued at $30,827,000 after acquiring an additional 158,284 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Radius Health in the third quarter valued at about $17,236,000.
Shares of Radius Health Inc (RDUS) opened at $37.71 on Thursday. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53. Radius Health Inc has a fifty-two week low of $24.66 and a fifty-two week high of $49.16.
In related news, major shareholder Growth N. V. Biotech acquired 75,000 shares of Radius Health stock in a transaction that occurred on Friday, February 9th. The stock was purchased at an average price of $34.38 per share, for a total transaction of $2,578,500.00. Following the completion of the purchase, the insider now directly owns 5,773,799 shares of the company’s stock, valued at $198,503,209.62. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 15.00% of the stock is owned by company insiders.
Several analysts have recently weighed in on the stock. Morgan Stanley assumed coverage on shares of Radius Health in a report on Monday, January 29th. They issued an “overweight” rating and a $57.00 target price on the stock. Citigroup reaffirmed a “hold” rating and issued a $43.00 target price on shares of Radius Health in a report on Monday, January 22nd. BidaskClub raised shares of Radius Health from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. JPMorgan Chase & Co. lowered their target price on shares of Radius Health from $70.00 to $60.00 and set an “overweight” rating on the stock in a report on Monday, February 12th. Finally, Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a report on Monday, January 8th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. Radius Health has a consensus rating of “Hold” and an average target price of $51.78.
WARNING: “Eversept Partners LLC Invests $6.18 Million in Radius Health Inc (RDUS) Stock” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/22/eversept-partners-llc-invests-6-18-million-in-radius-health-inc-rdus-stock.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.